Literature DB >> 28365531

Macrophage activation syndrome: A new complication of checkpoint inhibitors.

Nausicaa Malissen1, Julie Lacotte2, Aurélie Du-Thanh3, Caroline Gaudy-Marqueste4, Bernard Guillot5, Jean-Jacques Grob6.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28365531     DOI： 10.1016/j.ejca.2017.02.016

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN： 0959-8049            Impact factor:   9.162


× No keyword cloud information.
  13 in total

1.  Two cases of lung cancer with hemophagocytic lymphohistiocytosis caused by immune checkpoint inhibitors.

Authors:  Atsumasa Kurozumi; Hidenori Takahashi; Takayasu Watanabe; Yoshinobu Iwasaki
Journal:  Thorac Cancer       Date:  2021-03-30       Impact factor: 3.500

Review 2.  Hemophagocytic lymphohistiocytosis with immunotherapy: brief review and case report.

Authors:  Masood Sadaat; Sekwon Jang
Journal:  J Immunother Cancer       Date:  2018-06-05       Impact factor: 13.751

3.  Severe cytokine release syndrome resulting in purpura fulminans despite successful response to nivolumab therapy in a patient with pleomorphic carcinoma of the lung: a case report.

Authors:  Osamu Honjo; Terufumi Kubo; Fumiko Sugaya; Takahiro Nishizaka; Koji Kato; Yoshihiko Hirohashi; Hiroki Takahashi; Toshihiko Torigoe
Journal:  J Immunother Cancer       Date:  2019-04-03       Impact factor: 13.751

4.  Hematologic Complications of Immune Checkpoint Inhibitors.

Authors:  Elizabeth J Davis; Joe-Elie Salem; Arissa Young; Jennifer R Green; P Brent Ferrell; Kristin K Ancell; Benedicte Lebrun-Vignes; Javid J Moslehi; Douglas B Johnson
Journal:  Oncologist       Date:  2019-02-28

5.  Haemophagocytic lymphohistiocytosis in patients treated with immune checkpoint inhibitors: analysis of WHO global database of individual case safety reports.

Authors:  Roberta Noseda; Raffaela Bertoli; Laura Müller; Alessandro Ceschi
Journal:  J Immunother Cancer       Date:  2019-05-02       Impact factor: 13.751

6.  Clinical diagnosis and treatment recommendations for immune checkpoint inhibitor-related hematological adverse events.

Authors:  Junling Zhuang; Jianhua Du; Xiaoxiao Guo; Jiaxin Zhou; Lian Duan; Wei Qiu; Xiaoyan Si; Li Zhang; Yue Li; Xiaowei Liu; Hanping Wang; Daobin Zhou; Li Zhang
Journal:  Thorac Cancer       Date:  2020-02-03       Impact factor: 3.500

Review 7.  Breakthroughs in modern cancer therapy and elusive cardiotoxicity: Critical research-practice gaps, challenges, and insights.

Authors:  Ping-Pin Zheng; Jin Li; Johan M Kros
Journal:  Med Res Rev       Date:  2017-09-01       Impact factor: 12.944

Review 8.  Classical Hodgkin's Lymphoma in the Era of Immune Checkpoint Inhibition.

Authors:  Valli De Re; Laura Caggiari; Ombretta Repetto; Lara Mussolin; Maurizio Mascarin
Journal:  J Clin Med       Date:  2019-10-02       Impact factor: 4.241

Review 9.  [Clinical Diagnosis and Treatment Recommendations for Immune Checkpoint Inhibitor-related Hematological Adverse Events].

Authors:  Junling Zhuang; Jingting Zhao; Xiaoxiao Guo; Jiaxin Zhou; Lian Duan; Wei Qiu; Xiaoyan Si; Li Zhang; Yue Li; Xiaowei Liu; Hanping Wang; Daobin Zhou; Li Zhang
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2019-10-20

10.  Encephalitis Associated With Hemophagocytic Lymphohistiocytosis Secondary to Immune Checkpoint Inhibitors: An Unfamiliar Spin-Off.

Authors:  Ghulam Ghous; Hafiz Muhammad Hassan Shoukat; Zahid Ijaz Tarar; Muhammad Usman Zafar; Joseph W McGreevy
Journal:  Cureus       Date:  2021-06-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.